From: Evaluation of two strategies for the interpretation of tumour markers in pleural effusions
ALL | ADA<45; CRP<50; %PN<90 | ADA>45; CRP>50 or %PN>90 | |
---|---|---|---|
Malignant | 122 | 103 | 19 |
Lung cancer | 46 | 40 | 6 |
CUP | 18 | 16 | 2 |
Mesothelioma | 15 | 12 | 3 |
Breast cancer | 13 | 12 | 1 |
Lymphoma | 9 | 4 | 5 |
Bladder cancer | 5 | 5 | 0 |
Ovarian cancer/PSPCa | 3 | 3 | 0 |
Stomach cancer | 3 | 3 | 0 |
Cholangiocarcinoma | 2 | 0 | 2 |
Colon cancer | 2 | 2 | 0 |
Cervix cancer | 1 | 1 | 0 |
Endometrium cancer | 1 | 1 | 0 |
Hypernephroma | 1 | 1 | 0 |
Melanoma | 1 | 1 | 0 |
Multiple myeloma | 1 | 1 | 0 |
Pancreas cancer | 1 | 1 | 0 |
Cardiogenic | 69 | 56 | 13 |
Empyema | 11 | 1 | 10 |
Parapneumonic non complicated | 26 | 25 | 1 |
complicated | 14 | 2 | 12 |
Pneumonitis | 10 | 5 | 5 |
Tuberculous | 13 | 0 | 13 |
Paramalignant | 34 | 29 | 5 |
Viral | 10 | 8 | 2 |
Post traumatic | 6 | 6 | 0 |
Others: Pulmonary Embolism, Pericarditis, Cirrhotic, nephrotic syndrome, uremia, Rheumatoid arthritis etc. | 87 | 71 | 16 |
All | 402 | 306 | 96 |